A detailed history of Dafna Capital Management LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Dafna Capital Management LLC holds 704,500 shares of BCRX stock, worth $5.94 Million. This represents 1.12% of its overall portfolio holdings.

Number of Shares
704,500
Previous 709,500 0.7%
Holding current value
$5.94 Million
Previous $3.6 Million 20.78%
% of portfolio
1.12%
Previous 0.87%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.13 - $6.79 $20,650 - $33,950
-5,000 Reduced 0.7%
704,500 $4.35 Million
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $286,350 - $389,275
57,500 Added 8.82%
709,500 $4.25 Million
Q3 2023

Nov 14, 2023

BUY
$6.71 - $7.92 $556,930 - $657,360
83,000 Added 14.59%
652,000 $4.62 Million
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $121,800 - $154,175
17,500 Added 3.17%
569,000 $4.01 Million
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $2.39 Million - $3.56 Million
300,500 Added 119.72%
551,500 $4.6 Million
Q4 2022

Feb 14, 2023

BUY
$10.5 - $14.2 $2.64 Million - $3.56 Million
251,000 New
251,000 $2.88 Million
Q4 2020

Feb 16, 2021

SELL
$3.37 - $8.61 $2.52 Million - $6.45 Million
-749,051 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$3.43 - $5.53 $17,150 - $27,650
5,000 Added 0.67%
749,051 $2.57 Million
Q2 2020

Aug 14, 2020

BUY
$1.9 - $5.61 $503,500 - $1.49 Million
265,000 Added 55.32%
744,051 $3.55 Million
Q1 2020

May 15, 2020

SELL
$1.6 - $4.11 $56,000 - $143,850
-35,000 Reduced 6.81%
479,051 $958,000
Q4 2019

Feb 14, 2020

BUY
$1.59 - $3.45 $48,754 - $105,787
30,663 Added 6.34%
514,051 $1.77 Million
Q3 2019

Nov 14, 2019

BUY
$2.5 - $3.73 $181,250 - $270,425
72,500 Added 17.64%
483,388 $1.39 Million
Q2 2019

Aug 14, 2019

SELL
$2.91 - $9.15 $254,703 - $800,872
-87,527 Reduced 17.56%
410,888 $1.56 Million
Q1 2019

May 15, 2019

BUY
$7.38 - $9.72 $250,920 - $330,480
34,000 Added 7.32%
498,415 $4.06 Million
Q4 2018

Feb 14, 2019

SELL
$6.51 - $9.6 $1.22 Million - $1.8 Million
-187,671 Reduced 28.78%
464,415 $3.75 Million
Q3 2018

Nov 14, 2018

BUY
$5.52 - $7.99 $261,835 - $378,997
47,434 Added 7.84%
652,086 $4.98 Million
Q2 2018

Aug 13, 2018

SELL
$4.6 - $6.52 $1.7 Million - $2.41 Million
-370,000 Reduced 37.96%
604,652 $3.47 Million
Q1 2018

May 15, 2018

SELL
$4.35 - $5.82 $950,805 - $1.27 Million
-218,576 Reduced 18.32%
974,652 $4.65 Million
Q3 2017

Nov 14, 2017

BUY
$4.1 - $5.97 $4.89 Million - $7.12 Million
1,193,228
1,193,228 $6.25 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.57B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Dafna Capital Management LLC Portfolio

Follow Dafna Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.